Capstone Companies, Inc. (OTCQB: CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Shares of Novavax (NVAX) have gained 3.5% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if short-term price targets of ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

Traders continued to sell off major tech stocks that have been driving the bull market. Moderna stock sank as the company cut ...

These are jabs developed by Pfizer Biontech, Moderna and AstraZeneca. While the Novavax and the Sanofi GSK vaccines will not ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...